Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 948-040-6 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute Oral Toxicity; OECD 423; Dreher, D. (2017); LD50: >300 - 2000 mg/kg bw. Based on the cut-off value the LD50 used in the CSA is 500 mg/kg bw.
Acute Inhalation Toxicity; OECD 436; Bradshaw, J. (2018); LC50: >1 - 5 mg/L. Based on the cut-off value the LD50 used in the CSA is 2.5 mg/L.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 03 March - 30 November 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Study conducted in accordance with international guidelines and in accordance with GLP. All guideline valiity criteria were met.
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Version / remarks:
- European Community (EC). Council Regulation (EC) No 440/2008 (31 May 2008)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- 17 December 2001
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Version / remarks:
- December 2002
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: Appendix to Director General Notification, No. 12-Nousan-8147, Japanese Ministry of Agriculture, Forestry and Fisheries of Japan
- Version / remarks:
- November 2000
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
- Specific details on test material used for the study:
- RADIOLABELLING INFORMATION (if applicable)
- Radiochemical purity: N/A
- Specific activity: N/A
- Locations of the label: N/A
- Expiration date of radiochemical substance: N/A
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: 2-8 C, in the dark
- Stability under test conditions: Assumed stable
- Solubility and stability of the test substance in the solvent/vehicle: The test article was dispersed in corn oil for the 50 mg/kg dose level. Corn oil was chosen as it was capable of forming a homogeneous solution as described in Covance GLP Study 8359421.
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: No
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: The test article was used as supplied for dose levels of 300 and 2000 mg/kg. For the 50 mg/kg/day group, the test item was formulated in corn oil.
- Preliminary purification step (if any): N/A
- Final dilution of a dissolved solid, stock liquid or gel: Not reported
- Final preparation of a solid: N/A
FORM AS APPLIED IN THE TEST (if different from that of starting material) : Applied as supplied, or in a corn oil formulation (50 mg/kg/day group only)
TYPE OF BIOCIDE/PESTICIDE FORMULATION (if applicable) N/A
OTHER SPECIFICS: N/A - Species:
- rat
- Strain:
- Wistar
- Remarks:
- Crl:WI(Han)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, Margate, UK
- Females (if applicable) nulliparous and non-pregnant: Yes
- Age at study initiation: 7-10 weeks
- Weight at study initiation: The weight variation did not exceed ±20% of the mean weight.
- Fasting period before study: Night before dosing
- Housing: The animals were housed in groups of up to five during the acclimatisation period in suspended, solid floor cages with wire lids. From the day prior to dosing (Day-1), the rats were housed in groups of three in similar cages. Bedding was provided on a weekly basis to each cage by use of clean European soft wood bedding (Datesand Ltd., Manchester, UK). Each batch of bedding was analysed for specific constituents and contaminants. No contaminants were present in bedding at levels which might have interfered with achieving the objective of the study.
- Diet (e.g. ad libitum): Throughout the study the animals had access to 5LF2 EU Rodent Diet 14%, which was freely available to the animals at all times, except for a period of fasting from the evening of the day prior to dosing (Day-1) until approximately 3 hours after dosing. Each batch of diet had been analysed for specific constituents and contaminants by the manufacturer. No contaminants were present in diet at levels which might have interfered with achieving the objective of the study.
- Water (e.g. ad libitum): Mains water was provided ad libitum via cage mounted water bottles. The water was periodically analysed for specific contaminants. No contaminants were present in water at levels which might have interfered with achieving the objective of the study.
- Acclimation period: 6-15 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 45-65
- Air changes (per hr): 15-20
- Photoperiod (hrs dark / hrs light): 12:12
IN-LIFE DATES: From: 14 March 2017 To: 25 May 2017 - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Remarks:
- 50 mg/kg/day group only
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: Not reported
- Amount of vehicle (if gavage): 5 mL/kg bw
- Justification for choice of vehicle: Was found to form a homogenous formulation in Covance GLP Study 8359421. Corn oil is also an guideline recommended vehicle.
- Lot/batch no. (if required): Not reported
- Purity: Not reported
MAXIMUM DOSE VOLUME APPLIED: 5 mL/kg
DOSAGE PREPARATION (if unusual): N/A
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: N/A - Doses:
- 2000, 300 and 50 mg/kg
- No. of animals per sex per dose:
- 6 females (2 x groups of 3)
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Treated rats were observed closely for clinical signs of reaction to treatment. Clinical signs were recorded immediately post-dose, at approximately 15 and 30 minutes post- dose, hourly between 1 and 4 hours post-dose (inclusive), twice daily on Days 2, 3 and 4 and once daily from the fifth to last day of the observation period.
Individual body weights were recorded on Day-1 (day before dosing) and on Days 1, 4, 8 and 15. Decedent carcass weights were also recorded prior to necropsy
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, free-hand histopathology (sectioning) of liver and kidneys, examination of representative sections of mucosal surfaces of the stomach, small and large intestines - Statistics:
- No
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 300 - <= 2 000 mg/kg bw
- Based on:
- test mat.
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 500 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: result is based on the cut-off value as determined in Annex 2 of the OECD TG 423
- Mortality:
- 50 mg/kg = 0/6 mortality
300 mg/kg = 0/6 mortality
2000 mg/kg = 3/6 mortality - Clinical signs:
- other: Decreased activity and hunched posture were noted 3 and 4 hours after dosing, in one animal treated at 2000 mg/kg. Hypothermia, ptosis, piloerection, laboured breathing and prone posture were noted in the animal that was killed in extremis. No clinical si
- Gross pathology:
- No abnormalities were noted at necropsy of animals that died or were killed in extremis during the study or at necropsy of those that were killed at the end of the study.
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- Based of the experimental conditions of this study, the test article was classified as Category 4 in respect of its acute oral toxicity according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS).
- Executive summary:
OECD 423 (2017) - This study was conducted to assess the acute toxicity of the test article (Reaction Mass of N,N,N',N-tetrabutylmethylenediamine and dibutylamine), following a single oral administration to small groups of rats. The study design provides information for hazard assessment and classification and enables a chemical to be assigned to toxicity classes but severely restricts animal usage.
A group of fasted rats was given the test article as a single dose by oral gavage at a dose level of 2000 mg/kg bw (3F+3F). Based on the results from this dose level and from associated study (14 Day Oral DRF study), in the interest of animal welfare, the next dose level was 50 mg/kg bw (3F+3F). Then, 300 mg/kg bw was tested (3F+3F). Treatment of animals was sequential. Sufficient time was allowed between each group to confirm the survival of the previously dosed animals.
The test article was used undiluted for the 300 and 2000 mg/kg bw dose levels and was dispersed in corn oil for the 50 mg/kg bw dose level. Surviving animals were killed on Day 15. All animals underwent a full necropsy.
Two animals treated at 2000 mg/kg bw were found dead on Day 2. One other animal was humanely killed due to the severity of the clinical signs on this day.
There were no deaths at dose levels of 50 or 300 mg/kg bw.
Decreased activity and hunched posture were noted 3 and 4 hours after dosing, in one animal treated at 2000 mg/kg bw. Hypothermia, ptosis, piloerection, laboured breathing and prone posture were noted in the animal that was killed in extremis. No clinical signs were seen prior to death in the two animals that were found dead.
No clinical signs were seen in animals treated at 50 or 300 mg/kg bw.
All surviving rats achieved body weight gains during the first and second weeks of the study.
No abnormalities were noted at necropsy of animals that died or were killed in extremis during the study or at necropsy of those that were killed at the end of the study.
Based of the experimental conditions of this study, the test article was classified as Category 4 in respect of its acute oral toxicity according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS). Based on the observed effects the LD50 using the cut-off value was estimated to be 500 mg/kg bw bw.
Reference
Table 2 Number of animals dead (and with evident toxicity)
Dose (mg/kg bw) |
Mortality (# dead / total) |
Time range of deaths (hours) |
Number with evident toxicity (# / total) |
||||
Male |
Female |
Combined |
Male |
Female |
Combined |
||
2000 |
- |
3 / 6 |
3/ 6 |
24 -48 |
- |
2 / 6 |
2 / 6 |
300 |
- |
0 / 6 |
0 / 6 |
n/a |
- |
0 / 6 |
0 / 6 |
50 |
- |
0 / 6 |
0 / 6 |
n/a |
- |
0 / 6 |
0 / 6 |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 500 mg/kg bw
- Quality of whole database:
- The study is reliable and meets the data requirements according to the Registrants tonnage band submission (up to 100 T/y), according to the REACH Regulation (EC) No 1907/2006 Annex VII, Section 8.5.
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 10 August 2017 -
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Study was conducted in accordance with international guidelines and in accordance with GLP. All guideline validity criteria were met.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 436 (Acute Inhalation Toxicity: Acute Toxic Class Method)
- Deviations:
- yes
- Remarks:
- Exposure chamber humidity was not kept at 30-70 % in the second exposure. One animal was not weighed at death.
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.52 (Acute Inhalation Toxicity - Acute Toxic Class Method)
- Deviations:
- yes
- Remarks:
- Exposure chamber humidity was not kept at 30-70 % in the second exposure. One animal was not weighed at death.
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
- Specific details on test material used for the study:
- RADIOLABELLING INFORMATION (if applicable)
- Radiochemical purity: N/A
- Specific activity: N/A
- Locations of the label: N/A
- Expiration date of radiochemical substance: N/A
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: 2-8 ºC, in the dark
- Stability under test conditions: Confirmed by GC-MS analysis.
- Solubility and stability of the test substance in the solvent/vehicle: N/A
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: N/A
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: No
- Preliminary purification step (if any): No
- Final dilution of a dissolved solid, stock liquid or gel: No
- Final preparation of a solid: No
FORM AS APPLIED IN THE TEST (if different from that of starting material) : The test item was aerosolized using a metal concentric jet nebulizer (Envigo CRS Limited, UK) located at the top of the exposure chamber. The nebulizer was connected to a glass syringe attached to an infusion pump, which provided a continuous supply of test item under pressure, and to a metered compressed air supply.
TYPE OF BIOCIDE/PESTICIDE FORMULATION (if applicable) N/A
OTHER SPECIFICS: N/A - Species:
- rat
- Strain:
- Wistar
- Remarks:
- RccHan:WIST
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Envigo RMS (UK) Limited, Oxon, UK
- Females (if applicable) nulliparous and non-pregnant: Yes
- Age at study initiation: 8-12 weeks old
- Weight at study initiation: 200-300 g
- Fasting period before study: No
- Housing: The animals were housed in groups of up to three by sex in solid floor polypropylene cages with stainless steel lids, furnished with softwood flakes.
- Diet (e.g. ad libitum): Ad libitum; 2014C Teklad Global Rodent diet supplied by Envigo RMS (UK) Limited, Oxon, UK
- Water (e.g. ad libitum): Ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-25
- Humidity (%): 30-70 (apart from the second exposure 14 %)
- Air changes (per hr): ≥15
- Photoperiod (hrs dark / hrs light): 12:12
IN-LIFE DATES: From: 21 August 2017 To: 22 January 2018 - Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- nose only
- Vehicle:
- clean air
- Mass median aerodynamic diameter (MMAD):
- >= 2.11 - <= 2.22 µm
- Geometric standard deviation (GSD):
- >= 2.27 - <= 2.38
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: The test item was aerosolized using a metal concentric jet nebulizer (Envigo CRS Limited, UK) located at the top of the exposure chamber. The nebulizer was connected to a glass syringe attached to an infusion pump, which provided a continuous supply of test item under pressure, and to a metered compressed air supply. Compressed air was supplied by means of an oil free compressor and passed through a water trap and respiratory quality filters before it was introduced to the nebulizer.
- Exposure chamber volume: 30 L
- Method of holding animals in test chamber: During the exposure period, each rat was individually held in a tapered, polycarbonate restraining tube fitted onto a single tier of the exposure chamber and sealed by means of a rubber ‘O’ ring. Only the nose of each animal was exposed to the test atmosphere.
- Source and rate of air: 40 L/hour. Compressed air.
- Method of conditioning air: Compressed air was supplied by means of an oil free compressor and passed through a water trap and respiratory quality filters before it was introduced to the nebulizer.
- System of generating particulates/aerosols: The test item was aerosolized using a metal concentric jet nebulizer (Envigo CRS Limited, UK) located at the top of the exposure chamber.
- Method of particle size determination: The particle size of the generated atmosphere inside the exposure chamber was determined three times during the exposure period using a Marple Personal Cascade Impactor (Westech IS Ltd, Beds., UK).
- Treatment of exhaust air: The extract from the exposure chamber passed through a ‘scrubber’ trap and was connected with a high efficiency filter to a metered exhaust system.
- Temperature, humidity, pressure in air chamber: Temperature: 19-20 ºC; Humidity: 14-41 %; Air Pressure: Not reported
TEST ATMOSPHERE
- Brief description of analytical method used: The actual concentration of the test item was measured by determined by gas chromatography (GC) using an external standard technique. The test atmosphere was sampled after theoretical chamber equilibration and then at approximately 30 minute intervals during the exposure period. Samples were then submitted for analysis.
- Samples taken from breathing zone: Yes
VEHICLE
- Composition of vehicle (if applicable): N/A
- Concentration of test material in vehicle (if applicable): N/A
- Justification of choice of vehicle: N/A
- Lot/batch no. (if required): N/A
- Purity: N/A
TEST ATMOSPHERE (if not tabulated)
- Particle size distribution: The particle size of the generated atmosphere inside the exposure chamber was determined three times during the exposure period using a Marple Personal Cascade Impactor (Westech IS Ltd, Beds., UK). This device consisted of six impactor stages (10.4, 7.7, 4.1, 1.3, 0.90 and 0.56 µm cut points) with stainless steel collection substrates and a backup glass fiber filter, housed in an aluminum sampler. The sampler was temporarily sealed in a sampling port in the animals’ breathing zone and a suitable, known volume of exposure chamber air was drawn through it using a vacuum pump. The collection substrates and backup filter were weighed before and after sampling and the weight of test item, collected at each stage, calculated by difference. The mean amount for each stage was used to determine the cumulative amount below each cut off point size. In this way, the proportion (%) of aerosol less than 10.4, 7.7, 4.1, 1.3, 0.90 and 0.56 µm was calculated.
- MMAD (Mass median aerodynamic diameter) / GSD (Geometric st. dev.): The resulting values were converted to probits and plotted against Log10 cut point size. From this plot, the Mass Median Aerodynamic Diameter (MMAD) was determined (as the 50% point) and the geometric standard deviation was calculated. In addition the proportion (percentage) of aerosol less than 4 µm (considered to be the inhalable fraction) was determined.
CLASS METHOD (if applicable)
- Rationale for the selection of the starting concentration: As insufficient data was available on the expected inhalation toxicity of the test item, a sighting test was performed to determine the initial exposure concentration. A group of two animals (one male and one female) was exposed to an aerosol atmosphere of the test item at a target concentration of 1.0 mg/L. Based on the results of the sighting test, a limit test was performed. A group of six animals (three males and three females) was exposed to an aerosol atmosphere of the test item at a target concentration of 5.0 mg/L.
Due to a significant number of mortalities in the Limit Test, a further group of six animals (three males and three females) was exposed to an aerosol atmosphere of the test item at a target concentration of 1.0 mg/L. - Analytical verification of test atmosphere concentrations:
- yes
- Duration of exposure:
- 4 h
- Concentrations:
- Mean achieved concentrations:
5.67 mg/L and 1.02 mg/L (test protocol in accordance with OECD TG 436 Annex 3d) - No. of animals per sex per dose:
- 3 males and 3 females per test concentration
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing:
Clinical observations- All animals were observed for clinical signs at hourly intervals during exposure, immediately on removal from the restraining tubes at the end of exposure, 1 hour after termination of exposure and subsequently once daily for 14 days. Any deaths or evidence of overt toxicity was recorded at each observation.
Body weight - Individual body weights were recorded on arrival, prior to treatment on the day of exposure (Day 0) and on Days 1, 3, 7 and 14 or at death.
Necropsy- At the end of the 14 observation period surviving animals were killed by intravenous overdose of sodium pentobarbitone. All animals including those that died or were humanely killed during the study were subjected to a full external and internal examination and any macroscopic abnormalities were recorded. The respiratory tract was subjected to a detailed macroscopic examination for signs of irritancy or local toxicity.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, organ weights, necropsy - Statistics:
- Data evaluations included the relationship, if any, between the animals’ exposure to the test item and the incidence and severity of all abnormalities including behavioral and clinical observations, necropsy findings, body weight changes, mortality and any other toxicological effects. Using the mortality data obtained, an estimate of the acute inhalation median lethal concentration (LC50) of the test item was made
- Key result
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- > 1 - <= 5 mg/L air (nominal)
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Key result
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- > 1.02 - <= 5.67 mg/m³ air (analytical)
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Key result
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- 2.5 mg/L air (nominal)
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Remarks on result:
- other: result is based on the cut-off value as determined in Annex 3 of the OECD TG 436
- Mortality:
- 5.67 mg/L group: 3/3 males and 3/3 females
1.02 mg/L group: 0/3 males and 0/3 femlaes
Clinical observations: During exposure both animals exhibited decreased respiratory rate and wet fur. On removal from the chamber both animals exhibited decreased respiratory rate, lethargy, ataxia, hunched posture, pilo-erection, red/brown staining around the snout and wet fur. One hour post-exposure, decreased respiratory rate, ataxia and red/brown staining around the snout were no longer apparent.
On Day 1 post-exposure both animals exhibited hunched posture and noisy respiration was noted in the male. Decreased respiratory rate was exhibited by the male on Day 3 post-exposure. Animals recovered to appear normal from Days 3 to 4 post-exposure. - Clinical signs:
- irregular respiration
- Remarks:
- Decreased respiratory rate and wet fur during exposure. On removal from the chamber: decreased respiratory rate, lethargy, ataxia, hunched posture, pilo-erection, red/brown staining around the snout and wet fur (see above for further details).
- Body weight:
- 5.67 mg/L group: None of the animals survived until the end of the day of exposure and as such no significant body weight data was collected.
1.02 mg/L group: With the exception of one female, all animals showed body weight loss on Day 1 post exposure. Animals showed expected gains in body weight during the remainder of the recovery period with the exception of two males that showed body weight loss or no gain in body weight from Days 1 to 3 post-exposure, one female that showed no gain in body weight from Days 3 to 7 post-exposure and one female that showed no gain in body weight from Days 7 to 14 post-exposure. - Gross pathology:
- 5.67 mg/L group: The following macroscopic abnormalities were detected at necropsy of animals that died or were humanely killed during exposure:
Lungs – hemorrhagic, pale and/or abnormally red.
1.02 mg/L group: No macroscopic abnormalities were detected at necropsy of one animal that survived until the end of the recovery period.
The following macroscopic abnormalities were detected at necropsy of the remaining animals that survived until the end of the recovery period:
Lungs – pale, dark patches, abnormally red, abnormally dark.
Due to the observations noted during the study and at necropsy it is considered that the deaths noted during the study may have been mainly attributable to local toxicity. - Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- None of the animals died in a group of six rats exposed to a mean achieved atmosphere concentration of 1.02 mg/L. However, all animals died in a group of six rats exposed to a mean achieved atmosphere concentration of 5.67 mg/L. It was therefore considered that the acute inhalation median lethal concentration (4 hour LC50) of the test item, in the RccHanTM : WIST strain rat, should be considered to be > 1.0 – 5.0 mg/L (Globally Harmonized Classification System – Category 4). This equates to an LD50 based on the cut-off value of 2.5 mg/L.
- Executive summary:
OECD 436 (2018) - In an acute inhalation toxicity study, groups of young adult RccHan:WIST strain rats (6 male and 6 female) were exposed by inhalation route to Reaction Mass of N,N,N',N-tetrabutylmethylenediamine and dibutylamine for 4 hours to nose only at mean measured concentrations of 1.02 and 5.67 mg/L. Animals then were observed for 14 days after which time they were sacrificed and underwent necropsy.
Mortality
In the 5.67 mg/L group, all 6 rats were found dead within 102-170 minutes exposure. There was no mortality observed in the 1.02 mg/L group.
Clinical signs
5.67 mg/L group: During exposure all animals exhibited decreased respiratory rate. One animal died after 102 minutes of exposure, two animals died after 120 minutes of exposure. Labored respiration and gasping respiration were also exhibited by two of the surviving animals after 120 minutes of exposure. One animal died after 160 minutes of exposure and a further animal died after 170 minutes of exposure. Ataxia, hunched posture and areas of red/brown staining around the snout were also exhibited by the surviving animal after 180 minutes of exposure. This animal was humanely killed due to the occurrence of clinical signs of toxicity that were considered likely to exceed the severity limit set forth in the UK Home Office Project License after 230 minutes of exposure.
1.02 mg/L group: During exposure, on removal from the chamber and one hour post-exposure, all animals exhibited decreased respiratory rate. On removal from the chamber all animals exhibited ataxia, which was severe in one animal, and there were occasional instances of gasping respiration, labored respiration, noisy respiration, areas of red/brown staining around the snout with isolated instances of clonic convulsions, lethargy and areas of red/brown staining around the eyes. Improvement in the condition of the animals was noted one hour post-exposure.
One day after exposure, all animals exhibited hunched posture and one female also exhibited noisy respiration, pilo-erection and areas of red/brown staining around the eyes.
Animals recovered to appear normal from Days 2 to 5 post-exposure. One male that recovered to appear normal on Day 2 post-exposure subsequently exhibited sneezing on Day 3 post‑exposure. Sneezing was also exhibited by one female from Days 2 to 4 post-exposure.
Body Weight
5.67 mg/L group: None of the animals survived until the end of the day of exposure and as such no significant body weight data was collected.
1.02 mg/L group: With the exception of one female, all animals showed body weight loss on Day 1 post‑exposure. Animals showed expected gains in body weight during the remainder of the recovery period with the exception of two males that showed body weight loss or no gain in body weight from Days 1 to 3 post-exposure, one female that showed no gain in body weight from Days 3 to 7 post-exposure and one female that showed no gain in body weight from Days 7 to 14 post-exposure.
Necropsy
5.67 mg/L group: The following macroscopic abnormalities were detected at necropsy of animals that died or were humanely killed during exposure:
Lungs – hemorrhagic, pale and/or abnormally red.
1.02 mg/L group: No macroscopic abnormalities were detected at necropsy of one animal that survived until the end of the recovery period.
The following macroscopic abnormalities were detected at necropsy of the remaining animals that survived until the end of the recovery period:
Lungs – pale, dark patches, abnormally red, abnormally dark.
Due to the observations noted during the study and at necropsy it is considered that the deaths noted during the study may have been mainly attributable to local toxicity.
None of the animals died in a group of six rats exposed to a mean achieved atmosphere concentration of 1.02 mg/L. However, all animals died in a group of six rats exposed to a mean achieved atmosphere concentration of 5.67 mg/L. It was therefore considered that the acute inhalation median lethal concentration (4 hour LC50) of the test item, in the RccHanTM : WIST strain rat, should be considered to be > 1.0 – 5.0 mg/L (Globally Harmonized Classification System – Category 4). This equates to an LD50 based on the cut-off value of 2.5 mg/L.
Reference
Table 1 Mortality Data
Mean achieved atmosphere concentration (mg/L) |
Deaths |
||
Male |
Female |
Total |
|
5.67 |
3/3* |
3/3 |
6/6 |
1.02 |
0/3 |
0/3 |
0/6 |
* 1 male killed in extremis due to evert signs of clinical toxicity
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 2.5 mg/m³ air
- Physical form:
- inhalation: aerosol
- Quality of whole database:
- The study is reliable and meets the data requirements according to the Registrants tonnage band submission (up to 100 T/y), according to the REACH Regulation (EC) No 1907/2006 Annex VIII, Section 8.5.
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- the study does not need to be conducted because inhalation of the substance is likely
- Justification for type of information:
- JUSTIFICATION FOR DATA WAIVING
In line with the REACH regulation (EC no. 1907/2006) Annex VIII Section 8.5.3, Column 2, a study on the acute toxicity via the dermal route has not been conducted as inhalation is the most likely route of concern based on the substances physical chemical properties. Dibutylamine has harmonised classification and labelling, due, to the classification of dibutylamine and its percentage within the substance the substance will be classified as Acute Tox. Dermal Cat. 4. In line with the most recent self classification by the Lead Registrant.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
OECD 423 (2017) - This study was conducted to assess the acute toxicity of the test article (Reaction Mass of N,N,N',N-tetrabutylmethylenediamine and dibutylamine), following a single oral administration to small groups of rats. The study design provides information for hazard assessment and classification and enables a chemical to be assigned to toxicity classes but severely restricts animal usage.
A group of fasted rats was given the test article as a single dose by oral gavage at a dose level of 2000 mg/kg bw (3F+3F). Based on the results from this dose level and from associated study (14 Day Oral DRF study), in the interest of animal welfare, the next dose level was 50 mg/kg bw (3F+3F). Then, 300 mg/kg bw was tested (3F+3F). Treatment of animals was sequential. Sufficient time was allowed between each group to confirm the survival of the previously dosed animals.
The test article was used undiluted for the 300 and 2000 mg/kg bw dose levels and was dispersed in corn oil for the 50 mg/kg bw dose level. Surviving animals were killed on Day 15. All animals underwent a full necropsy.
Two animals treated at 2000 mg/kg bw were found dead on Day 2. One other animal was humanely killed due to the severity of the clinical signs on this day.
There were no deaths at dose levels of 50 or 300 mg/kg bw.
Decreased activity and hunched posture were noted 3 and 4 hours after dosing, in one animal treated at 2000 mg/kg bw. Hypothermia, ptosis, piloerection, laboured breathing and prone posture were noted in the animal that was killed in extremis. No clinical signs were seen prior to death in the two animals that were found dead.
No clinical signs were seen in animals treated at 50 or 300 mg/kg bw.
All surviving rats achieved body weight gains during the first and second weeks of the study.
No abnormalities were noted at necropsy of animals that died or were killed in extremis during the study or at necropsy of those that were killed at the end of the study.
Based of the experimental conditions of this study, the test article was classified as Category 4 in respect of its acute oral toxicity according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS). Based on the observed effects the LD50 using the cut-off value was estimated to be 500 mg/kg bw.
OECD 436 (2018) - In an acute inhalation toxicity study, groups of young adult RccHan:WIST strain rats (6 male and 6 female) were exposed by inhalation route to Reaction Mass of N,N,N',N-tetrabutylmethylenediamine and dibutylamine for 4 hours to nose only at mean measured concentrations of 1.02 and 5.67 mg/L. Animals then were observed for 14 days after which time they were sacrificed and underwent necropsy.
Mortality
In the 5.67 mg/L group, all 6 rats were found dead within 102-170 minutes exposure. There was no mortality observed in the 1.02 mg/L group.
Clinical signs
The following observations considered to be associated with the restraint procedure were detected: Wet fur was noted both during and for a short period after exposure. Hunched posture and pilo-erection were noted on removal and for a short period on removal from the chamber.
5.67 mg/L group: During exposure all animals exhibited decreased respiratory rate. One animal died after 102 minutes of exposure, two animals died after 120 minutes of exposure. Labored respiration and gasping respiration were also exhibited by two of the surviving animals after 120 minutes of exposure. One animal died after 160 minutes of exposure and a further animal died after 170 minutes of exposure. Ataxia, hunched posture and areas of red/brown staining around the snout were also exhibited by the surviving animal after 180 minutes of exposure. This animal was humanely killed due to the occurrence of clinical signs of toxicity that were considered likely to exceed the severity limit set forth in the UK Home Office Project License after 230 minutes of exposure.
1.02 mg/L group: During exposure, on removal from the chamber and one hour post-exposure, all animals exhibited decreased respiratory rate. On removal from the chamber all animals exhibited ataxia, which was severe in one animal, and there were occasional instances of gasping respiration, labored respiration, noisy respiration, areas of red/brown staining around the snout with isolated instances of clonic convulsions, lethargy and areas of red/brown staining around the eyes. Improvement in the condition of the animals was noted one hour post-exposure.
One day after exposure, all animals exhibited hunched posture and one female also exhibited noisy respiration, pilo-erection and areas of red/brown staining around the eyes.
Animals recovered to appear normal from Days 2 to 5 post-exposure. One male that recovered to appear normal on Day 2 post-exposure subsequently exhibited sneezing on Day 3 post‑exposure. Sneezing was also exhibited by one female from Days 2 to 4 post-exposure.
Body Weight
5.67 mg/L group: None of the animals survived until the end of the day of exposure and as such no significant body weight data was collected.
1.02 mg/L group: With the exception of one female, all animals showed body weight loss on Day 1 post‑exposure. Animals showed expected gains in body weight during the remainder of the recovery period with the exception of two males that showed body weight loss or no gain in body weight from Days 1 to 3 post-exposure, one female that showed no gain in body weight from Days 3 to 7 post-exposure and one female that showed no gain in body weight from Days 7 to 14 post-exposure.
Necropsy
5.67 mg/L group: The following macroscopic abnormalities were detected at necropsy of animals that died or were humanely killed during exposure:
Lungs – hemorrhagic, pale and/or abnormally red.
1.02 mg/L group: All Group 2 animals survived until the end of the recovery period. No macroscopic abnormalities were detected at necropsy for one animal that survived until the end of the recovery period.
The following macroscopic abnormalities were detected at necropsy of the remaining Group 2 animals:
Lungs – pale, dark patches, abnormally red, abnormally dark.
Due to the observations noted during the study and at necropsy it is considered that the deaths noted during the study are mainly attributable to local toxicity.
None of the animals died in a group of six rats exposed to a mean achieved atmosphere concentration of 1.02 mg/L. However, all animals died in a group of six rats exposed to a mean achieved atmosphere concentration of 5.67 mg/L. It was therefore considered that the acute inhalation median lethal concentration (4 hour LC50) of the test item, in the RccHanTM : WIST strain rat, should be considered to be > 1.0 – 5.0 mg/L (Globally Harmonized Classification System – Category 4). This equates to an LD50 based on the cut-off value of 2.5 mg/L.
Acute dermal toxicity:
In line with the Lead Registrants most recent self classification dibutylamine is classified as acute dermal toxicity (Harmonised classification, Category 4 / LR self-classification, Category 3) (sourced February 2023: https://echa.europa.eu/substance-information/-/substanceinfo/100.003.565).
The classification of O7017 should be done using the CLP additivity formula, based on information on its constituents (CAS 111-92-2 & CAS 20280-10-8):
100 / ATEmix = (C/ATE CAS 111-92-2) + (C/ATE CAS 20280-10-8) = (% CAS 111-92-2/768 mg/kg bw) + (% 20280-10-8/1100 mg/kg bw)
Using upper range of CAS 20280-10-8 / lower range of CAS 111-92-2:
100 / ATEmix = (C/ATE CAS 111-92-2) + (C/ATE CAS 20280-10-8) = (10%/768 mg/kg bw) + (85%/1100 mg/kg bw)
ATEmix = ca. 1107 mg/kg bw
Using upper range of CAS 111-92-2 / lower range of CAS 202280-10-8
100 / ATEmix = (C/ATE CAS 111-92-2) + (C/ATE CAS 20280-10-8) = (25%/768 mg/kg bw) + (65%/1100 mg/kg bw)
ATEmix = ca. 1091 mg/kg bw
Note 1: the LD50 for CAS 20280-10-8 was not available, therefore the converted acute toxicity point estimated derived using Table 3.1.2 of the CLP was used (1100 mg/kg bw).
Note 2: This calculation is based on the upper and lower range of the boundary calculation.
Justification for classification or non-classification
Harmonised classification:
The substance has no harmonised classification for acute toxicity according to the Regulation (EC) No. 1272/2008 (CLP).
Self classification:
Acute toxicity via Oral route:
Based on the available information, the substance is classified in Category 4 according to the CLP and the GHS as the LD50 is between 300 and 2000 mg/kg bw
Acute toxicity via Dermal route:
Using the additivity approach, the substance is classified in Category 4 according to the CLP and the GHS
Acute toxicity via Inhalation:
Based on the available information, the substance is classified in Category 4 according to the CLP and the GHS as the LC50 is between 1 and 5 mg/L (aerosol).
Specific target organ toxicity: single exposure (Oral):
The classification criteria according to the CLP and to the GHS as specific target organ toxicant (STOT) – single exposure, oral are not met since no reversible or irreversible adverse health effects were observed immediately or delayed after exposure and no effects were observed at the guidance value (oral) for a Category 1 classification (C≤ 300 mg/kg bw) and at the guidance value (oral) for a Category 2 classification (2000 mg/kg bw≥C > 300 mg/kg bw). No classification is required.
The criteria for Transient Organ effects (STOT-SE Category 3) according to the CLP and to the GHS are not met since narcotic effects were not observed in the acute oral toxicity study.
Specific target organ toxicity: single exposure (Dermal):
No study is available.
Specific target organ toxicity: single exposure (Inhalation):
The classification criteria according to the CLP and the GHS as specific target organ toxicant (STOT) – single exposure, inhalation are not met since no reversible or irreversible adverse health effects were observed immediately or delayed after exposure and no effects were observed at the guidance value (inhalation / aerosol) for a Category 1 classification (C ≤ 1 mg/L/4h) and at the guidance value (inhalation) for a Category 2 classification (5 mg/L/4h ≥ C > 1 mg/L/4h). No classification is required.
The criteria for Transient Organ effects (STOT-SE Category 3) according to the CLP and to the GHS are not met since narcotic effects were not observed in the acute dermal toxicity study.
Aspiration hazard:
The substance is not a hydrocarbon and no effects were observed on lungs in oral studies, therefore the criteria for aspiration toxicity according to the CLP and to the GHS are not met.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.